Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 23, 2017
Pharmacy Choice - News - Generic Drugs - August 23, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 65     Next >>     Go To Page:

8/23/17 - Argentum Pharmaceuticals and Eli Lilly Settle Patent Dispute Over CIALIS
Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement and license agreement with Eli Lilly and Company related to Argentum's generic version of CIALIS . The agreement generally provides that Argentum may commence marketing its generic product no earlier than September 27, 2018.
8/22/17 - ACR Applauds Initiatives to Speed FDA Biosimilar Approvals
The American College of Rheumatology issued the following statement by Sharad Lakhanpal, president on initiatives to speed FDA biosimilar approvals:. The bill, which passed both chambers of Congress with overwhelming bipartisan support, reauthorizes the U.S. Food and Drug Administration's user fee agreements for prescription drugs, generic drugs,..
8/22/17 - CSPC Pharmaceutical Announces 2017 Interim Results
CSPC Pharmaceutical Group Limited, a leading pharmaceutical company in China, is pleased to announce its interim results for the six months ended 30 June 2017. During the Period, the Group recorded sales of approximately HK $7,202 million, representing an increase of 17.2% over the same period of last year. Profit attributable to shareholders was
8/22/17 - Drug firms sell off plants [Sport360]
Perrigo, a big generics maker, agreed to sell its active pharmaceutical ingredient facility in Israel to SK Capital, a private equity firm, for $110 million. Last year it acquired Noramco and Tasmanian Alkaloids, sister opioid manufacturers, from Johnson& Johnson. Bristol-Myers Squibb will sell a biologic drug plant in Bothell, Wash., to Seattle Ge
8/22/17 - Endo to Participate at Morgan Stanley Global Healthcare Conference
Endo International plc announced today that Paul Campanelli, President and CEO, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 12, 2017 at 11:45 a.m. ET. Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medi
8/22/17 - IFC INVESTS IN NOBEL ILAC TO IMPROVE ACCESS TO HIGH-QUALITY MEDICINE IN TURKEY
Release date- 21082017- IFC, a member of the World Bank Group, is providing a $25 million loan to Nobel Ilac, a leading pharmaceutical company in Turkey and the country's only net exporter in the sector, to help meet the growing demand for innovative, affordable, and high-quality medicine in Turkey. Turkey is largely dominated by branded generic pr
8/22/17 - Japan Biosimilars Markets 2017 - The Start of Authorized Biosimilar Era? - Research and Markets
The " Japan Biosimilars- The Start of Authorized Biosimilar Era?" In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, and current trend of biosimilars use in Japan. The report provide all the Japanese/Global players' activities in biosimilar space for Japan market along with their pipeline
8/22/17 - Japan Biosimilars Research Report 2017: Major JP Innovator vs. Early Entrant Mid Size Japanese Companies - TA focus approach - A Win Win Game
In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, and current trend of biosimilars use in Japan. The report provide all the Japanese/Global players' activities in biosimilar space for Japan market along with their pipeline deal history, current Mab tech platforms, alliances and deal stru
8/22/17 - OncBioMune Submits Documents to Commercialize Norepinefrine in Mexico
On June 19, 2017, the Company announced acquiring the sanitary registration and intellectual property rights to Norepinefrine in Mexico and other markets from the Mexican subsidiary of the world s biggest generic drug company. OncBioMune is presently negotiating details to bring Norepinefrine manufacturing to a state-of-the-art facility in Latin
8/22/17 - Samsung Bioepis, Takeda agree to develop biosimilar drugs [Arab Finance (Egypt)]
Samsung Bioepis and Takeda Pharmaceutical have signed a strategic collaboration agreement to develop new biopharmaceuticals, Samsung Bioepis said Monday. Takeda Pharmaceutical also showed enthusiasm for the cooperative agreement. The company is collaborating with Merck, a global Pharmaceutical company, also known as MSD in Korea.
8/22/17 - SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) and Maintains Price Target of $0.65
NEW YORK, NY/ ACCESSWIRE/ August 22, 2017/ SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. and maintained its price target of $0.65. Innovus Pharmaceuticals, Inc. is a fast-growing commercial s
8/22/17 - Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%, Emollient
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has received approval of the Company s abbreviated new drug application from the U.S. Food and Drug Administration of Clobetasol Propionate Cream USP, 0.05%, Emollient. Clobetasol Propionate Cream USP, 0.05%, Emollient is Teligent s fourth FD
8/21/17 - Biosimilar insulin lispro shown not inferior to Humalog in efficacy or safety
By a News Reporter-Staff News Editor at Clinical Trials Week New Rochelle, NY, A study comparing the safety and efficacy of SAR342434, a biosimilar of insulin lispro-Humalog , found it to be comparable to that of the brand name drug in patients also using insulin glargine. Coauthors Satish Garg, University of Colorado Denver, Karin Wernicke-Pan
8/21/17 - EpiPen maker finalizes settlement for government overcharges
TRENTON, N.J.- EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade- charges brought after rival Sanofi filed a whistleblower lawsuit and tipped off the government. On Thursday, the Department of Justice disclosed that its EpiPen case began
8/21/17 - Erelzi (etanercept), by Sandoz, is now available for patients in Canada for the treatment of multiple inflammatory diseases
Erelzi? has been approved for use in Canada in a manner similar to Enbrel , for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Polyarticular Juvenile Idiopathic Arthritis 1. First biosimilar approved to treat juvenile idiopathic arthritis. Erelzi TM is the second Sandoz biosimilar available in Canada, strengthening Sandoz' l
8/21/17 - Global Biosimilars Market Size and Forecast 2014-2017 & 2025 - Focus on Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides
In addition, the study focuses on a wealth of information on Biosimilars producers and suppliers. Key Topics:- Identify Biosimilars market size for the year 2013-2015 and forecast the same till 2025- Deriving data for Biosimilars, By Region, By Type and By Application- Identify major driving factors, restraints, challenges for the Biosimilars- and
8/21/17 - Global Biosimilars Market Size and Forecast 2014-2025 - Research and Markets
The "Global Biosimilars Market Size and Forecast" report has been added to Research and Markets' offering. The main objective of the study is to estimate the global market size of the Biosimilars in terms of the value, and forecast of the same till 2025.. -Deriving data for Biosimilars, By Region, By Type and By Application.
8/21/17 - IFC Invests in Nobel Ilac To Improve Access To High-Quality Medicine in Turkey
ISTANBUL, 21 August 2017/ PRNewswire Policy/ IFC, a member of the World Bank Group, is providing a $25 million loan to Nobel Ilac, a leading pharmaceutical company in Turkey and the country's only net exporter in the sector, to help meet the growing demand for innovative, affordable, and high-quality medicine in Turkey. Turkey is largely dominate
8/21/17 - Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
By a News Reporter-Staff News Editor at AIDS Weekly Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V., a leading global pharmaceutical company, announced the launch in Canada of three generic products indicated in the treatment of HIV for certain patients. Mylan received final approval from Health Canada for this product and for...
8/21/17 - SK Capital Announces Agreement to Acquire Perrigo Company plc's Active Pharmaceutical Ingredients Business
By a News Reporter-Staff News Editor at Pharma Business Week SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced that it has signed a definitive agreement to acquire Perrigo API, Perrigo Company plc's active pharmaceutical ingredients business. SK Capital has effectively execu
8/21/17 - Teva Announces Exclusive Launch of Generic Axiron in the United States
Release date- 18082017- JERUSALEM- Teva Pharmaceutical Industries Ltd., today announced the launch of generic Axiron1 topical solution CIII, 30 mg/1. 5 mL, in the U.S.. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportuni
8/21/17 - Upsher-Smith Launches Newly Designed Website For Qudexy XR (topiramate) Extended-Release Capsules
Upsher-Smith Laboratories, LLC today announced the launch of its enhanced website for Qudexy XR Extended-Release Capsules. The site features Upsher-Smith's Access Pathways? Program designed to reduce the barriers associated with prescribing Qudexy XR. QudexyXR.com offers healthcare professionals the tools necessary to help their patients.
8/21/17 - WHAT THE OTHER PAPERS SAY THIS MORNING
FINANCIAL TIMES LAW GIANT QUITS ADVISING BARCLAYS OVER QATAR LOAN Law firm Linklaters resigned from advising Barclays over a controversial loan to Qatar at the heart of a $1 bn lawsuit over fears it would be illegal, court documents have claimed. HIKMA HIKES PRICE OF US MEDICINES BY UP TO 430 PC Hikma, the London- listed generic drugmaker, has shar
8/20/17 - BRIEF: Teva launches generic testosterone boost treatment [Globes, Tel Aviv, Israel]
Aug. 20 Teva Pharmaceutical Industries Ltd. has announced the launch of generic Axiron topical solution CIII, 30 mg/1. 5 mL, in the US. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending fir
8/20/17 - Mylan finalizes settlement over Medicaid payments for EpiPen
PITTSBURGH Generic drug giant Mylan announced Thursday it has finalized its settlement with the U.S. Department of Justice for overcharging Medicaid for the EpiPen. The settlement amount is $465 million, unchanged from when Mylan announced a preliminary deal in October that was criticized by lawmakers and others as not being harsh enough.
Articles(s): 1 - 25 of 65     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415